Novo Nordisk has questioned the FDA to block manufacture of compounded copies of copyright, arguing that it’s much too difficult to do safely. It’s the latest escalation inside of a brewing war between pharmaceutical providers and compounders.The Connected Push is undoubtedly an unbiased international news Group dedicated to factual reporting.